Pharmafile Logo
Pharmafocus logo
Advanced Search

Manufacturing and Production

Showing 15 posts of 5866 posts found.

stocks1

Weekly Movers: Array BioPharma, Amicus Therapeutics, Genocea Biosciences, Tesaro Inc, Incyte, Clovis Oncology

April 11, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Index, Movers, markets, stocks

Shares in Botox-maker Allergan (NYSE: AGN) plunged over 17% in intra-day trading as the $160 billion merger seal with US …
Feature
genome

UK’s genomics and personalised medicine expertise showcased at major international gathering

April 8, 2016 Manufacturing and Production, Research and Development 000 genomics project, 100, NHS, UK, expertise, genomics, international gathering, world leader

The UK’s expertise in genomics was showcased at a major international gathering to foster global collaboration in this burgeoning field. …
News
foundry

UK’s first commercial synthetic biology foundry begins production

April 7, 2016 Manufacturing and Production, Research and Development Biological, biologics, foundry, synbicite

SynbiCITE’s has begun production at the UK’s first commercial synthetic biology foundry. The site provides automated end-to-end design, construction and …
News
handshake

Allergan to partner with Heptares in Alzheimer’s disease collaboration

April 7, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Alzheimer's, Heptares, R&D, collaboration, commercialisation, h1, h4, neurological disorders, partnership, research and development, treatments

Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan (NYSE:AGN) has announced a new …
News
pfizer_building

5 things to know about the Pfizer/Allergan inversion collapse

April 6, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 5, 5 things, Allergan, Pfizer, collapse, inversion, reasons

The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …
Feature
manufacturing

Sun to cut jobs in Irish facility closure; Lilly announce further investment in the country

April 6, 2016 Manufacturing and Production, Research and Development Eli Lilly, Ireland, Kinsale, Sun Pharma, cashel, investment, lilly

There was mixed news for pharmaceutical manufacturing in Ireland as Sun Pharma announced its decision to close its facility based …
News
celltrion

Celltrion’s biosimilar for J&J’s arthritis drug gets UF FDA okay

April 6, 2016 Manufacturing and Production, Research and Development

Korea-based Celltrion (Kosdaq: 068270) has received US regulatory approval for its biosimilar version of the arthritis drug marketed by Johnson …
News
samsung

Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis

Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
News
clinical_trials_2

Flexion Therapeutics announce results for Zilretta trials in osteoarthritis pain

April 5, 2016 Manufacturing and Production, Research and Development drugs, flexion, flexion therapeutics, osteoarthritis, pipeline, treatments, zilretta

Flexion Therapeutics has presented positive results from two pivotal clinical trials for its lead drug candidate, Zilretta, which show that …
News
descovy

FDA approves Gilead’s latest HIV treatment

April 5, 2016 Manufacturing and Production, Research and Development Gilead, HIV, descovy, taf, taf-based, therapy

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration has approved their TAF-based HIV therapy, Descovy (emtricitabine, …
News
gilead-sciences

Gilead to buy Nimbus Therapeutics’ unit, trial drug for up to $1.2 billion

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Gilead Sciences, M&A, MA, Nimbus Apollo, Nimbus Therapeutics, merger and acquisitions

Gilead Sciences (Nasdaq: GILD) has agreed to buy a unit of biotechnology firm Nimbus Therapeutics and its trial drug to …
News
legal

Janssen and Genmab sued for patent infringement in US

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement

German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).
News
aldridge_roboty_thing

Outsourcing and Robots: how smart pharmas are optimising R&D operations

April 5, 2016 Manufacturing and Production

Faced with steadily rising research and development costs, as well as increasingly stringent regulatory requirements, pharmaceutical firms are re-evaluating their …
Feature
stats_data

Timeline of turmoil – Valeant Pharmaceuticals’ troubled March 2016

April 4, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Share price, Valeant, fall, month from hell, timeline, turmoil

As far as months go, March 2016 couldn’t have gone much worse for Valeant Pharmaceuticals. The Canada-based company has been …
Feature

FTC files complaint against Endo for blocking generics of its pain drugs

April 1, 2016 Business Services, Manufacturing and Production, Medical Communications, Sales and Marketing Endo International, FTC, legal, regulation

The US Federal Trade Commission (FTC) has filed a complaint against Endo International (Nasdaq: ENDP) alleging the company used illegal …
News
The Gateway to Local Adoption Series

Latest content

IsomAb appoints Philip Brainin as CEO

March 19, 2026

Naobios partners with SGS to manufacture RSV challenge agent

March 19, 2026

Qlaris Bio appoints Fred Guerard as President and CEO

March 18, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

March 18, 2026

AEON Biopharma appoints John Bencich as CFO

March 17, 2026